Table 2.
Publication identification and study characteristics between adult and pediatric studies.
| All ages | Adult | Pediatric | |
|---|---|---|---|
| Number of total studies, n (%) | 66 (100) | 45 (68) | 21 (32) |
| Year, n (%) | |||
| 2020–2022 | 15 (23) | 9 (20) | 6 (29) |
| 2010–2019 | 43 (65) | 28 (62) | 15 (71) |
| 2000–2009 | 4 (9.1) | 4 (8.9) | 0 |
| 1990–1999 | 2 (3.0) | 2 (4.4) | 0 |
| <1990 | 2 (3.0) | 2 (4.4) | 0 |
| Country of origin, n (%) | |||
| USA | 34 (52) | 22 (49) | 12 (57) |
| Canada | 8 (12) | 7 (16) | 1 (4.8) |
| Germany | 5 (7.6) | 4 (8.9) | 1 (4.8) |
| Australia | 3 (4.6) | 2 (4.4) | 1 (4.8) |
| Egypt | 2 (3.0) | 2 (4.4) | 0 |
| UK | 2 (3.0) | 0 | 2 (9.5) |
| Argentina | 1 (1.5) | 1 (2.2) | 0 |
| Chile | 1 (1.5) | 0 | 1 (4.8) |
| France | 1 (1.5) | 0 | 1 (4.8) |
| Ireland | 1 (1.5) | 0 | 1 (4.8) |
| Italy | 1 (1.5) | 1 (2.2) | 0 |
| Jamaica | 1 (1.5) | 1 (2.2) | 0 |
| Lithuania | 1 (1.5) | 1 (2.2) | 0 |
| Mexico | 1 (1.5) | 0 | 1 (4.8) |
| Nigeria | 1 (1.5) | 1 (2.2) | 0 |
| Poland | 1 (1.5) | 1 (2.2) | 0 |
| South Africa | 1 (1.5) | 1 (2.2) | 0 |
| Spain | 1 (1.5) | 1 (2.2) | 0 |
| Publication type, n (%) | |||
| Journal article | 46 (70) | 32 (71) | 14 (67) |
| Abstract | 18 (27) | 12 (27) | 6 (29) |
| Thesis | 2 (3.0) | 2 (4.4) | 0 |
| Journal/conference, n (%) | |||
| Epilepsy and behavior | 17 (26) | 9 (20) | 8 (38) |
| AAN annual meeting | 6 (9.0) | 5 (11) | 1 (4.8) |
| AES annual meeting | 2 (3.0) | 2 (4.4) | 0 |
| Epilepsia | 2 (3.0) | 1 (2.2) | 1 (4.8) |
| European congress on epileptology | 3 (3.0) | 2 (4.4) | 1 (4.8) |
| JAMA | 2 (3.0) | 2 (4.4) | 0 |
| Other journals | 25 (37.9) | 19 (42.2) | 6 (28.6) |
| Other conferences | 7 (10.6) | 3 (6.7) | 4 (19.0) |
| University thesis | 2 (3.0) | 2 (4.4) | 0 |
| Potentially significant funding/conflict of interest, n (%) | |||
| Yes | 7 (11) | 2 (4.4) | 5 (24) |
| No | 59 (89) | 43 (96) | 16 (76) |
| Study type, n (%) | |||
| Cross-sectional | 45 (68) | 35 (78) | 10 (48) |
| Case report/series | 14 (21) | 8 (18) | 6 (29) |
| Qualitative | 3 (4.6) | 0 | 3 (14) |
| Cohort | 3 (4.6) | 1 (2.2) | 2 (9.5) |
| Case-control | 1 (1.5) | 1 (2.2) | 0 |
| Sample, n (%) | |||
| PWE | 35 (53) | 28 (62) | 7 (33) |
| PWE using cannabis | 23 (35) | 9 (20) | 14 (67) |
| Cannabis users | 5 (7.6) | 5 (11) | 0 |
| PWE and medical professionals | 1 (1.5) | 1 (2.2) | 0 |
| Medical professionals | 1 (1.5) | 1 (2.2) | 0 |
| Patients with neurological disorders | 1 (1.5) | 1 (2.2) | 0 |
| Sample type, n (%) | |||
| Convenience | 35 (53) | 22 (49) | 13 (62) |
| Consecutive | 16 (24) | 13 (29) | 3 (14) |
| Snowball | 2 (3.0) | 1 (2.2) | 1 (4.8) |
| Unknown | 2 (3.0) | 2 (4.4) | 0 |
| N/A (e.g., case report) | 11 (17) | 7 (16) | 4 (19) |
| Sample size, median (range) | |||
| Number of total study participants, median (range) | 95 (1–657,072) | 132 (1–657,072) | 31 (1–378) |
| Number of PWE using NMC, median (range) | 24.5 (1–37,945) | 26 (1–37,945) | 23.5 (1–272) |
AACPDM, American Academy for Cerebral Palsy and Developmental Medicine; AAN, American Academy of Neurology; AES, American Epilepsy Society; CNSF, Canadian Neurological Sciences Federation; ILAE, International League Against Epilepsy; n, count; NMC, non-medical cannabis; PWE, people with epilepsy.